news
Anthropic starts making its own drugs
Anthropic, the AI lab behind Claude, said it will begin developing its own drug pipeline rather than only licensing models to pharma. Early focus is expected on repurposed molecules and metabolic/inflammation indications.
Anthropic, the AI lab behind Claude, said it will begin developing its own drug pipeline rather than only licensing models to pharma. Early focus is expected on repurposed molecules and metabolic/inflammation indications.
The architecture take
The interesting number is not the science — it is the stack. Same company owns the model reading your biometrics, the molecule, and the refill cadence. Diagnosis inflation is the business plan; a strong baseline is the only edit nobody can push remotely.